This Raw Listing contains the General
Information Section and up to the first 5 pages.

ENTERED

```
1                           SEQUENCE LISTING
2
3    (1)     General Information:
4
5    (i)APPLICANT: Evans, Mark J.
6                  Matis, Louis A.
7                  Mueller, Eileen Elliott
8                  Nye, Steven H.
9                  Rollins, Scott
10                 Rother, Russell P.
11                 Springhorn, Jeremy P.
12                 Squinto, Stephen P.
13                 Thomas, Thomas C.
14                 Wilkins, James A.
15
16   (ii)TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT
17       OF INFLAMMATORY DISEASES
18
19       (iii) NUMBER OF SEQUENCES: 26
20
21   (iv) CORRESPONDENCE ADDRESS:
22   (A)ADDRESSEE:  Seth A. Fidel
23   (B)STREET:  25 Science Park (Alexion)
24   (C)CITY:  New Haven
25   (D)STATE:  Connecticut
26   (E)COUNTRY:  USA
27   (F)ZIP:  06511
28
29   (v)COMPUTER READABLE FORM:
30   (A)MEDIUM TYPE:  3.5 inch, 1.4Mb storage
31   (B)COMPUTER:  Macintosh Cetris 610
32   (C)OPERATING SYSTEM:  System 7
33   (D)SOFTWARE:  WordPerfect 3.0
34   (vi)CURRENT APPLICATION DATA:
35   (A)APPLICATION NUMBER:08/487,283
36   (B)FILING DATE: June 7, 1995
37      (vii)PRIOR APPLICATION DATA:
38   (A)APPLICATION NUMBER: US 08/236,208
39   (B)FILING DATE:  02-MAY-1994
40
41      (viii)ATTORNEY/AGENT INFORMATION:
42   (A)NAME:  Seth A. Fidel.
43   (B)REGISTRATION NUMBER: 38,449
44   (C)REFERENCE/DOCKET NUMBER:  ALX-152.1 CIP
45   (ix)TELECOMMUNICATION INFORMATION:
46   (A)TELEPHONE:  (203)776-1790
```

```
47    (B)TELEFAX:   (203)772-3655
48
49
50
51    (2) INFORMATION FOR SEQ ID NO:1:
52    (i) SEQUENCE CHARACTERISTICS:
53    (A) LENGTH:  21 amino acids
54    (B) TYPE:  Amino Acid
55    (C) STRANDEDNESS:  Single
56    (D) TOPOLOGY:  Linear
57    (ii) MOLECULE TYPE:
58    (A) DESCRIPTION:  KSSKC peptide
59    (iii) HYPOTHETICAL:  No
60    (iv) ANTI-SENSE:  No
61
62    (xi) SEQUENCE DESCRIPTION:  SEQ ID NO:1:
63
64    Val Ile Asp His Gln Gly Thr Lys Ser Ser
65                     5                    10
66
67    Lys Cys Val Arg Gln Lys Val Glu Gly Ser Ser
68                     15                   20
69
70
71    (2) INFORMATION FOR SEQ ID NO:2:
72        (i) SEQUENCE CHARACTERISTICS:
73            (A) LENGTH:  1676 Amino Acids
74            (B) TYPE:  Amino Acid
75            (C) STRANDEDNESS:  Single
76            (D) TOPOLOGY:  Linear
77      (ii) MOLECULE TYPE:
78      (A) DESCRIPTION:  Pro-C5 Polytpeptide
79      (iii) HYPOTHETICAL:  No
80      (iv) ANTI-SENSE:  No
81      (vi) ORIGINAL SOURCE:
82          (A) ORGANISM:  Homo sapiens
83      (x) PUBLICATION INFORMATION:
84          (A) AUTHORS:   Haviland, D.L.
85                         Haviland, J.C.
86                         Fleischer, D.T.
87                         Hunt, A.
88                         Wetsel, R.A.
89
90          (B) TITLE:  Complete cDNA Sequence of Human
91                      Complement Pro-C5
92          (C) JOURNAL: Journal of Immunology
93          (D) VOLUME:  146
94          (F) PAGES:  362-368
95          (G) DATE:  1991
96
97
98    (xi) SEQUENCE DESCRIPTION:  SEQ ID NO:2:
99
```

INPUT SET: S16458.raw

```
100                   Met Gly Leu Leu Gly Ile Leu Cys Phe Leu
101                            -15             -10
102
103   Ile Phe Leu Gly Lys Thr Trp Gly Gln Glu Gln Thr Tyr Val
104            -5              -1                    5
105
106   Ile Ser Ala Pro Lys Ile Phe Arg Val Gly Ala Ser Glu Asn
107            10              15                    20
108
109   Ile Val Ile Gln Val Tyr Gly Tyr Thr Glu Ala Phe Asp Ala
110            25                    30
111
112   Thr Ile Ser Ile Lys Ser Tyr Pro Asp Lys Lys Phe Ser Tyr
113    35              40              45
114
115   Ser Ser Gly His Val His Leu Ser Ser Glu Asn Lys Phe Gln
116       50              55              60
117
118   Asn Ser Ala Ile Leu Thr Ile Gln Pro Lys Gln Leu Pro Gly
119       65              70              75
120
121   Gly Gln Asn Pro Val Ser Tyr Val Tyr Leu Glu Val Val Ser
122           80              85              90
123
124   Lys His Phe Ser Lys Ser Lys Arg Met Pro Ile Thr Tyr Asp
125           95              100
126
127   Asn Gly Phe Leu Phe Ile His Thr Asp Lys Pro Val Tyr Thr
128   105           110              115
129
130   Pro Asp Gln Ser Val Lys Val Arg Val Tyr Ser Leu Asn Asp
131       120              125              130
132
133   Asp Leu Lys Pro Ala Lys Arg Glu Thr Val Leu Thr Phe Ile
134       135              140              145
135
136   Asp Pro Glu Gly Ser Glu Val Asp Met Val Glu Glu Ile Asp
137           150              155              160
138
139   His Ile Gly Ile Ile Ser Phe Pro Asp Phe Lys Ile Pro Ser
140           165              170
141
142   Asn Pro Arg Tyr Gly Met Trp Thr Ile Lys Ala Lys Tyr Lys
143   175           180              185
144
145   Glu Asp Phe Ser Thr Thr Gly Thr Ala Tyr Phe Glu Val Lys
146     190              195              200
147
148   Glu Tyr Val Leu Pro His Phe Ser Val Ser Ile Glu Pro Glu
149       205              210              215
150
151   Tyr Asn Phe Ile Gly Tyr Lys Asn Phe Lys Asn Phe Glu Ile
152           220              225              230
```

```
153
154   Thr Ile Lys Ala Arg Tyr Phe Tyr Asn Lys Val Val Thr Glu
155               235             240
156
157   Ala Asp Val Tyr Ile Thr Phe Gly Ile Arg Glu Asp Leu Lys
158   245             250             255
159
160   Asp Asp Gln Lys Glu Met Met Gln Thr Ala Met Gln Asn Thr
161       260             265             270
162
163   Met Leu Ile Asn Gly Ile Ala Gln Val Thr Phe Asp Ser Glu
164       275             280             285
165
166   Thr Ala Val Lys Glu Leu Ser Tyr Tyr Ser Leu Glu Asp Leu
167               290             295             300
168
169   Asn Asn Lys Tyr Leu Tyr Ile Ala Val Thr Val Ile Glu Ser
170               305             310
171
172   Thr Gly Gly Phe Ser Glu Glu Ala Glu Ile Pro Gly Ile Lys
173   315             320             325
174
175   Tyr Val Leu Ser Pro Tyr Lys Leu Asn Leu Val Ala Thr Pro
176       330             335             340
177
178   Leu Phe Leu Lys Pro Gly Ile Pro Tyr Pro Ile Lys Val Gln
179       345             350             355
180
181   Val Lys Asp Ser Leu Asp Gln Leu Val Gly Gly Val Pro Val
182               360             365             370
183
184   Ile Leu Asn Ala Gln Thr Ile Asp Val Asn Gln Glu Thr Ser
185               375             380
186
187   Asp Leu Asp Pro Ser Lys Ser Val Thr Arg Val Asp Asp Gly
188   385             390             395
189
190   Val Ala Ser Phe Val Leu Asn Leu Pro Ser Gly Val Thr Val
191       400             405             410
192
193   Leu Glu Phe Asn Val Lys Thr Asp Ala Pro Asp Leu Pro Glu
194       415             420             425
195
196   Glu Asn Gln Ala Arg Glu Gly Tyr Arg Ala Ile Ala Tyr Ser
197               430             435             440
198
199   Ser Leu Ser Gln Ser Tyr Leu Tyr Ile Asp Trp Thr Asp Asn
200               445             450
201
202   His Lys Ala Leu Leu Val Gly Glu His Leu Asn Ile Ile Val
203   455             460             465
204
205   Thr Pro Lys Ser Pro Tyr Ile Asp Lys Ile Thr His Tyr Asn
```

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/487,283A

INPUT SET: S16458.raw

```
206         470                      475                      480
207
208   Tyr Leu Ile Leu Ser Lys Gly Lys Ile Ile His Phe Gly Thr
209           485                  490                  495
210
211   Arg Glu Lys Phe Ser Asp Ala Ser Tyr Gln Ser Ile Asn Ile
212           500                  505                      510
213
214   Pro Val Thr Gln Asn Met Val Pro Ser Ser Arg Leu Leu Val
215               515                  520
216
217   Tyr Tyr Ile Val Thr Gly Glu Gln Thr Ala Glu Leu Val Ser
218   525                  530                  535
219
220   Asp Ser Val Trp Leu Asn Ile Glu Glu Lys Cys Gly Asn Gln
221       540                  545                  550
222
223   Leu Gln Val His Leu Ser Pro Asp Ala Asp Ala Tyr Ser Pro
224           555                  560                  565
225
226   Gly Gln Thr Val Ser Leu Asn Met Ala Thr Gly Met Asp Ser
227               570                  575                  580
228
229   Trp Val Ala Leu Ala Ala Val Asp Ser Ala Val Tyr Gly Val
230               585                  590
231
232   Gln Arg Gly Ala Lys Lys Pro Leu Glu Arg Val Phe Gln Phe
233   595                  600                  605
234
235   Leu Glu Lys Ser Asp Leu Gly Cys Gly Ala Gly Gly Gly Leu
236       610                  615                  620
237
238   Asn Asn Ala Asn Val Phe His Leu Ala Gly Leu Thr Phe Leu
239           625                  630                      635
240
241   Thr Asn Ala Asn Ala Asp Asp Ser Gln Glu Asn Asp Glu Pro
242           640                  645                      650
243
244   Cys Lys Glu Ile Leu Arg Pro Arg Arg Thr Leu Gln Lys Lys
245               655                  660
246
247   Ile Glu Glu Ile Ala Ala Lys Tyr Lys His Ser Val Val Lys
248   665                  670                  675
249
250   Lys Cys Cys Tyr Asp Gly Ala Cys Val Asn Asn Asp Glu Thr
251       680                  685                  690
252
253   Cys Glu Gln Arg Ala Ala Arg Ile Ser Leu Gly Pro Arg Cys
254           695                  700                  705
255
256   Ile Lys Ala Phe Thr Glu Cys Cys Val Val Ala Ser Gln Leu
257               710                  715                  720
258
```

PAGE: 1

SEQUENCE VERIFICATION REPORT
PATENT APPLICATION . US/08/487,283A

DATE: 03/24/97
TIME: 17:17:42

INPUT SET: S16458.raw

Line	Error	Original Text